课题基金 / 基金详情

Core C- Clinical and Translational Core

Core C- Clinical and Translational Core
核心 C- 临床和转化核心
批准号:
10468806
负责人:
Steven Mark Rowe
金额:
$22.65万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-04-01 至 2023-04-30

项目摘要

项目成果

Steven Mark Rowe的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY / ABSTRACT Experimental techniques that require measurements in cystic fibrosis (CF) patients and tissues have demonstrated clear utility in CF science. Such capabilities have enabled advances including important contributions to our understanding of basic aspects of disease pathogenesis, characterization of novel therapeutics directed towards CF ion transport defects, and the evaluation of CFTR modulators in human subjects. The purpose of Core C is to provide resources, expertise, and support to a wide variety of CF scientists to assist projects with a strong translational focus requiring human subject interaction and measurements in patients. To this end, Core C carries out three main functions as delineated in the Specific Aims. First, the Core designs and conducts in vivo measurements of CFTR activity in human subjects. This includes measures of ion transport (nasal, lower airway, and sinus potential difference), which are diagnostic of the CF defect and can be used to monitor the response to agents such as CFTR modulators that alter ion transport pathways, as well as other means of assessing CFTR activity (e.g., sweat chloride, sweat rate, etc.). Second, the Core conducts cardinal measures of mucus clearance in vivo, leveraging high-impact techniques including one micron resolution optical coherence tomography (μOCT) for in vivo use by endoscopic probes (complementing ex vivo and in vitro imaging in Core A); whole-lung mucociliary clearance measurement by Tc99 clearance; and mucus rheology and solid content assessment. And third, the Core provides support for the execution of CF clinical studies. Clinical trial design and regulatory support; collection and storage of biospecimens; and support for key clinical outcome measures that require careful technqiue in infants, children, and adults with CF are included. By employing a standard set of techniques, reagents, technical and regulatory support, and equipment in a centralized facility, Core C helps to maximize consistency of assays, efficiency of human subject involvement, and regulatory processes. Numerous projects within this P30 require in vivo assays of CFTR and clinical outcome, whereas in vivo measurements of the mucociliary transport apparatus by μOCT and other related techniques have a high demand and are capabilities unique to our Center. In addition, the Core drives cost savings by eliminating the need for establishing identical equipment in multiple laboratories and promoting economy-of-scale for production analysis and storage of clinical data. Overall, P30 Core C conducts studies well-integrated into the overall themes of the UAB P30, and provides capabilities and resources not otherwise available to individual CF laboratories at our Institution and beyond.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
UAB U-SPECT6CTUHROI Imager
Therapeutic targeting of MUC5B in a novel ferret model of idiopathic pulmonary fibrosis
Therapeutic targeting of MUC5B in a novel ferret model of idiopathic pulmonary fibrosis
Therapeutic targeting of MUC5B in a novel ferret model of idiopathic pulmonary fibrosis
海外基金